Soleno Therapeutics (SLNO) FCF Margin (2015 - 2026)
Soleno Therapeutics' (SLNO) quarterly FCF Margin came in at 27.46% in Q1 2026, down 48.23% on a QoQ basis from 53.03% in Q4 2025.
Soleno Therapeutics (SLNO) FCF Margin (2015 - 2026) Analysis & Trends
Soleno Therapeutics (SLNO) has 5 years of FCF Margin data on file, last reported at 27.46% in Q1 2026.
- On a quarterly basis, FCF Margin changed N/A year-over-year to 27.46% in Q1 2026; TTM through Mar 2026 was 37.0%, a N/A change from a year earlier, with the FY2025 full-year figure at 24.54%, changed N/A from the prior year.
- FCF Margin for Q1 2026 stood at 27.46%, down from 53.03% in the prior quarter.
- Over the last five years, FCF Margin for SLNO reached as high as 65.88% in Q3 2025 and fell as low as 38.77% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 10.45% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Soleno Therapeutics | 874.25 Mn | 618.67 Mn | 93.41 Mn | 27.46% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 27.46% |
| Dec 31, 2025 | 53.03% |
| Sep 30, 2025 | 65.88% |
| Jun 30, 2025 | -38.77% |
| Jun 30, 2017 | -382,500.00% |
| Mar 31, 2017 | -510.57% |
| Dec 31, 2016 | -182.99% |
| Sep 30, 2016 | -855.62% |
| Jun 30, 2016 | -202,000.00% |
| Mar 31, 2016 | -895.53% |
| Dec 31, 2015 | -814.17% |
| Sep 30, 2015 | -1,273.28% |
| Jun 30, 2015 | -2,337.11% |
| Mar 31, 2015 | -8,222.73% |